<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1 )*
---------
SARGENT, INC.
--------------------------------------------------------
(Name of Issuer)
Common Stock
--------------------------------------------------------
(Title of Class of Securities)
803659101
--------------------------------------------------------
(CUSIP Number)
Medipace Medical Group, Inc., Attn: Victor Gura, M.D.
5901 West Olympic Boulevard, Suite 300, Los Angeles, California 90036
(213) 935-5700
--------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
May 11, 1996
--------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box / /.
Check the following box if a fee is being paid with the statement / /. (A
fee is not required only if the reporting person: (1) has a previous statement
on file reporting beneficial ownership of more than five percent of the class
of securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.
(See Rule 13d-7.)
NOTE: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are to
be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(Continued on following page(s))
Page 1 of 14 Pages
---
<PAGE>
CUSIP No. 803659101 SCHEDULE 13D Page 2 of 14 Pages
--------- --- ---
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above
Persons
Medipace Medical Group, Inc. (95-3915465)
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) /X/
of a Group* (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Source of Funds*
00
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
State of California (USA)
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 1,000,000
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting Power
0
--------------------------------------------------
(9) Sole Dispositive Power
1,000,000
--------------------------------------------------
(10) Shared Dispositive Power
0
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
1,000,000
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
15.76%
- -------------------------------------------------------------------------------
(14) Type of Reporting Person*
CO
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 803659101 SCHEDULE 13D Page 3 of 14 Pages
--------- --- ---
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above
Persons
Victor Gura, M.D. (###-##-####)
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) /X/
of a Group* (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Source of Funds*
00
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
(USA)
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 2,183,036
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting Power
2,051,092
--------------------------------------------------
(9) Sole Dispositive Power
2,183,036
--------------------------------------------------
(10) Shared Dispositive Power
1,000,000
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
4,234,128
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
66.73%
- -------------------------------------------------------------------------------
(14) Type of Reporting Person*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 803659101 SCHEDULE 13D Page 4 of 14 Pages
--------- --- ---
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above
Persons
Ronald P. Lang, M.D. (###-##-####)
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) /X/
of a Group* (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Source of Funds*
00
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
(USA)
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 0
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting Power
1,727,679
--------------------------------------------------
(9) Sole Dispositive Power
727,679
--------------------------------------------------
(10) Shared Dispositive Power
1,000,000
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
1,727,679
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
27.23%
- -------------------------------------------------------------------------------
(14) Type of Reporting Person*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
CUSIP No. 803659101 SCHEDULE 13D Page 5 of 14 Pages
--------- --- ---
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above
Persons
Avraham H. Uncyk, M.D. (###-##-####)
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) /X/
of a Group* (b) / /
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Source of Funds*
00
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings is Required Pursuant to
Items 2(d) or 2(e)
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
(USA)
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 0
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting Power
1,323,413
--------------------------------------------------
(9) Sole Dispositive Power
323,413
--------------------------------------------------
(10) Shared Dispositive Power
1,000,000
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
1,323,413
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares*
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
20.86%
- -------------------------------------------------------------------------------
(14) Type of Reporting Person*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
<PAGE>
Page 6 of 14 Pages
SARGENT, INC.
AMENDMENT NO. 1
TO
SCHEDULE 13 D
Victor Gura, M.D., Ronald P. Lang, M.D.,
Avraham Uncyk, M.D. and Medipace Medical Group, Inc.
May 28, 1996
1. SECURITY AND ISSUER.
Common Stock
Sargent, Inc.
5901 West Olympic Boulevard
Suite 109
Los Angeles, California 90036
2. IDENTITY AND BACKGROUND.
VICTOR GURA, M.D.
a. Victor Gura, M.D.
b. 5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
c. Medical doctor (internal medicine/nephrology)
Medipace Medical Group, Inc.
5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
Los Angeles Community Dialysis, Inc.
5901 West Olympic Boulevard
Suite 109
Los Angeles, California 90036
d. Not applicable
e. Not applicable
f. United States of America
<PAGE>
Page 7 of 14 Pages
RONALD P. LANG, M.D.
a. Ronald P. Lang, M.D.
b. 5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
c. Medical doctor (internal medicine/nephrology)
Medipace Medical Group, Inc.
5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
Los Angeles Community Dialysis, Inc.
5901 West Olympic Boulevard
Suite 109
Los Angeles, California 90036
d. Not applicable
e. Not applicable
f. United States of America
AVRAHAM UNCYK, M.D.
a. Avraham Uncyk, M.D.
b. 5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
c. Medical doctor (internal medicine/endocrinology)
Medipace Medical Group, Inc.
5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
Los Angeles Community Dialysis, Inc.
5901 West Olympic Boulevard
Suite 109
Los Angeles, California 90036
d. Not applicable
e. Not applicable
f. United States of America
<PAGE>
Page 8 of 14 Pages
MEDIPACE MEDICAL GROUP, INC.
a. Medipace Medical Group, Inc.,
a California corporation
b. 5901 West Olympic Boulevard
Suite 300
Los Angeles, California 90036
c. General family medical practice
d. Not applicable
e. Not applicable
f. California
3. SOURCES AND AMOUNT OF FUNDS OR OTHER CONSIDERATION; and
4. PURPOSE OF TRANSACTION.
On May 11, 1996, Sargent, Inc. ("Sargent"), Los Angeles Community
Dialysis, Inc. ("LACD"), Victor Gura, M.D. ("Gura"), Avraham H. Uncyk, M.D.
("Uncyk") and Ronald P. Lang, M.D. ("Lang") completed the transaction
contemplated by an Agreement for the Exchange of Stock (the "Share Exchange
Agreement"), dated as of May 9, 1996. In connection with the Share Exchange
Agreement, Sargent issued an aggregate of 4,234,128 shares (the "Exchanged
Sargent Shares") of the common stock, par value $0.01 per share (the "Common
Stock") of Sargent to Gura, Uncyk and Lang in exchange for 100% of the issued
and outstanding shares (the "Exchanged LACD Shares") of common stock of LACD,
as follows: (i) Gura (2,183,036 shares), (ii) Lang (727,679 shares), (iii)
Uncyk (323,413 shares), and (iv) Medipace Medical Group, Inc. ("Medipace"), a
California corporation owned by Gura, Lang and Uncyk (1,000,000 shares). The
1,000,000 shares issued to Medipace were originally issued to Gura, Lang and
Uncyk in their proportionate ownership interests in Medipace (67.5%, 22.5%
and 10%, respectively), and subsequently transferred to Medipace.
Prior to the completion of the Share Exchange Agreement, Sargent had issued
and outstanding 2,111,343 shares of Common Stock. At the closing (the
"Closing") of the Share Exchange Agreement, Sargent had 6,345,471 shares of
Common Stock issued and outstanding. As a result, the Exchanged Sargent Shares
constituted approximately 66.73% of the issued and outstanding shares of Common
Stock of Sargent at the Closing.
Further, in connection with the Share Exchange Agreement, Gura and Lang
became members of the Board of Directors of Sargent, and it is anticipated that
the members of the Board of Directors of Sargent prior to the Closing will
resign from their positions and that Uncyk will become a director of Sargent ten
(10) days following the filing and mailing to Sargent's stockholders of the
<PAGE>
Page 9 of 14 Pages
information required under Rule 14f-1 of the Securities Exchange Act of 1934, as
amended.
Further, up to an additional 4,210,644 shares of Common Stock and warrants
to purchase up to 500,000 shares of Common Stock may be issued in the aggregate
to Gura, Uncyk and Lang on the following basis, in the event that Sargent meets
certain financial conditions based on the results of operations of Sargent as of
the end of the fiscal years ending December 31, 1996 or December 31, 1997: (i)
Gura (2,842,185 shares and 337,500 warrants), (ii) Lang (947,395 shares and
112,500 warrants), and (iii) Uncyk (421,064 shares and 50,000 warrants), which
reflects the percentage distribution ratio for the initial issuance of the
Exchanged Sargent Shares to Gura, Lang and Uncyk, respectively.
5. INTEREST IN SECURITIES OF THE ISSUER.
VICTOR GURA, M.D.
a. 4,234,128 shares (66.3%)
b. SOLE VOTING AND DISPOSITIVE POWERS - 2,183,036 shares (See Item 4)
SHARED VOTING POWER - 2,051,092 shares (See Items 2 and 6)
SHARED DISPOSITIVE POWER - 1,000,000 shares (See Items 2 and 6)
c. Not applicable
d. See Item 6
e. Not applicable
RONALD P. LANG, M.D.
a. 1,727,679 shares (27.23%)
b. SOLE VOTING POWER - none (See Item 6)
SHARED VOTING POWER - 1,727,679 shares (See Items 2 and 6)
SOLE DISPOSITIVE POWER - 727,679 shares (See Item 2)
SHARED DISPOSITIVE POWER - 1,000,000 shares (See Item 2)
c. Not applicable
d. See Item 6
e. Not applicable
<PAGE>
Page 10 of 14 Pages
AVRAHAM UNCYK, M.D.
a. 1,323,413 shares (20.86%)
b. SOLE VOTING POWER - none (See Item 6)
SHARED VOTING POWER - 1,323,413 shares (See Items 2 and 6)
SOLE DISPOSITIVE POWER - 323,413 shares (See Item 2)
SHARED DISPOSITIVE POWER - 1,000,000 shares (See Item 2)
c. Not applicable
d. See Item 6
e. Not applicable
MEDIPACE MEDICAL GROUP, INC.
a. 1,000,000 shares (15.76%)
b. SOLE VOTING AND DISPOSITIVE POWERS - 1,000,000 shares
SHARED VOTING AND DISPOSITIVE POWERS - none
c. Not applicable
d. See Item 6
e. Not applicable
Item 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
Of the 1,000,000 shares registered in the name of Medipace, 600,000 of such
shares are pledged as collateral for certain obligations of Medipace pursuant to
certain pledge agreements. Further, an additional 93,500 shares registered in
the name of Dr. Gura are pledged as collateral for such obligations. So long as
such obligations are not in default, Medipace and Gura directs the voting of
their respective pledged shares. However, the issued and outstanding shares of
Medipace are also pledged as collateral for such obligations.
The remaining 3,140,128 shares collectively owned by Gura, Uncyk and Lang
have been deposited in escrow, and are subject to certain restrictions on
transferability and alienation until certain obligations of Medipace have been
paid in full. Further, the remaining 3,140,128 shares may be required to be
pledged as collateral for such obligations in the event that all of the
1,000,000 shares registered in the name of Medipace are sold pursuant to such
pledge agreements.
Further, Lang, and Uncyk have granted Gura a proxy to vote the 1,051,092
shares collectively owned by Lang and Uncyk during the one year period
commencing May 11, 1996.
<PAGE>
Page 11 of 14 Pages
7. MATERIAL TO BE FILED AS EXHIBITS.
a. Agreement for Exchange of Stock, dated as of May 9, 1996
The Agreement for Exchange of Stock, dated as of May 9, 1996, which
constitutes an exhibit to this Schedule 13D, has been filed as an exhibit to the
Current Report on Form 8-K, dated May 24, 1996, as filed by the Company with the
Securities and Exchange Commission, and which document is incorporated herein by
this reference.
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief. I
certify that the information set forth in this statement is true, complete and
correct.
May 24, 1996 /s/ Victor Gura, M.D.
- ----------------- ----------------------------------------
Date Signature
Victor Gura, M.D.
----------------------------------------
Name/Title
May 24, 1996 /s/ Ronald P. Lang, M.D.
- ----------------- ----------------------------------------
Date Signature
Ronald P. Lang, M.D.
----------------------------------------
Name/Title
May 24, 1996 /s/ Avraham H. Uncyk, M.D.
- ----------------- ----------------------------------------
Date Signature
Avraham H. Uncyk, M.D.
----------------------------------------
Name/Title
